Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of “Moderate Buy” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) has received a consensus rating of “Moderate Buy” from the twenty ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $84.59.

A number of equities research analysts have commented on the stock. Oppenheimer decreased their price objective on shares of Intellia Therapeutics from $115.00 to $93.00 and set an “outperform” rating on the stock in a report on Friday, February 24th. EF Hutton Acquisition Co. I decreased their price objective on shares of Intellia Therapeutics from $123.00 to $116.00 and set a “buy” rating on the stock in a report on Friday, February 24th. Citigroup raised shares of Intellia Therapeutics from a “sell” rating to a “neutral” rating and decreased their price objective for the stock from $48.00 to $39.00 in a report on Tuesday, January 24th. JPMorgan Chase & Co. decreased their price objective on shares of Intellia Therapeutics from $82.00 to $79.00 and set an “overweight” rating on the stock in a report on Friday, March 31st. Finally, Sanford C. Bernstein assumed coverage on shares of Intellia Therapeutics in a report on Tuesday, March 21st. They set an “outperform” rating and a $54.00 price objective on the stock.

Institutional Trading of Intellia Therapeutics

Several hedge funds have recently bought and sold shares of NTLA. Wipfli Financial Advisors LLC acquired a new stake in Intellia Therapeutics during the 3rd quarter worth approximately $25,000. CWM LLC raised its holdings in Intellia Therapeutics by 2,072.7% during the 4th quarter. CWM LLC now owns 717 shares of the company’s stock worth $25,000 after buying an additional 684 shares during the period. Signaturefd LLC raised its holdings in Intellia Therapeutics by 149.1% during the 1st quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $30,000 after buying an additional 474 shares during the period. Sandia Investment Management LP acquired a new stake in shares of Intellia Therapeutics in the fourth quarter valued at approximately $35,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Intellia Therapeutics in the fourth quarter valued at approximately $38,000. 85.61% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Up 5.6 %

Shares of Intellia Therapeutics stock opened at $45.76 on Tuesday. The stock has a market capitalization of $4.03 billion, a P/E ratio of -8.49 and a beta of 1.86. The company has a 50-day simple moving average of $38.57 and a 200 day simple moving average of $40.79. Intellia Therapeutics has a 12-month low of $32.44 and a 12-month high of $76.45.

Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last announced its earnings results on Thursday, May 4th. The company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.41) by $0.24. The business had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $11.76 million. Intellia Therapeutics had a negative net margin of 804.94% and a negative return on equity of 41.67%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter last year, the company posted ($1.96) EPS. On average, equities analysts anticipate that Intellia Therapeutics will post -5.57 earnings per share for the current year.

About Intellia Therapeutics

(Get Rating)

Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.